Hyrimoz (Adalimumab)

Hyrimoz is a biologic disease‑modifying antirheumatic drug that targets the TNF‑α pathway in inflammatory autoimmune diseases.

• Rheumatoid arthritis: reduces joint inflammation and slows disease progression.
• Psoriatic arthritis: alleviates joint pain and skin lesions.
• Ankylosing spondylitis: improves spinal mobility and reduces pain.
• Crohn's disease: induces and maintains remission of intestinal inflammation.
• Ulcerative colitis: helps achieve clinical remission and mucosal healing.
• Plaque psoriasis: decreases skin scaling and erythema.

• Adalimumab binds with high affinity to soluble and membrane‑bound tumor necrosis factor‑alpha (TNF‑α), preventing its interaction with p55 and p75 cell surface receptors. By neutralising TNF‑α, the drug interrupts a key pro‑inflammatory cascade, leading to reduced recruitment of immune cells, decreased cytokine production, and attenuation of chronic inflammatory processes underlying autoimmune disorders.

Adalimumab may cause a range of adverse reactions, from mild to severe. Patients should be aware of both common and serious possibilities.

Common Side Effects

• Injection site reactions: redness, swelling, or pain at the injection site.
• Upper respiratory infections: sinusitis, nasopharyngitis, or bronchitis.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal discomfort.
• Rash: mild skin eruptions.
• Fatigue: feeling unusually tired.

Serious or Rare Side Effects

• Serious infections: tuberculosis, bacterial sepsis, or opportunistic infections.
• Malignancies: lymphoma or other cancers.
• Demyelinating disease: new or worsening neurologic symptoms.
• Heart failure: worsening of pre‑existing cardiac conditions.
• Lupus‑like syndrome: development of auto‑immune symptoms.
• Cytopenias: low blood cell counts such as neutropenia or anemia.

Before initiating therapy with Hyrimoz, clinicians should evaluate several safety considerations.

• Screen for active infections: test for tuberculosis, hepatitis B/C, and HIV.
• Assess vaccination status: avoid live vaccines during treatment.
• Monitor for malignancy: conduct regular cancer screenings as indicated.
• Evaluate cardiac function: use caution in patients with heart failure.
• Review laboratory values: monitor complete blood count and liver enzymes periodically.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Adalimumab can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Live vaccines: may cause severe infection.
• Concurrent biologic immunosuppressants: increase risk of serious infections.
• Severe active infection: therapy should be withheld.

Moderate Interactions (Monitor Closely)

• Methotrexate: may enhance immunosuppression; monitor blood counts.
• Azathioprine or 6‑mercaptopurine: increased infection risk.
• Cyclosporine: potential additive immunosuppressive effect.
• Non‑live vaccines: may have reduced efficacy; assess response.
• NSAIDs: monitor for gastrointestinal bleeding when combined with steroids.